Abstract
Immunosuppressed organ transplant recipients have an increased risk of developing cancer such as Kaposi’s sarcoma and posttransplant lymphoproliferative disorders (PTLDs) [1–3]. After organ transplantation, about 40% of patients with PTLDs survive, either because of spontaneous resolution after the cessation of immunosuppressive therapy, or possibly because of the efficacy of antiviral drugs, monoclonal antibodies and chemoradiotherapy [4]. Determination of the best treatment is difficult because of the limited number of published series, and because of the morphologic spectrum of the lymphoproliferative disorders which appears to range from a benign reactive lymphoid process to a malignant lymphoma. We reexamined our experience of 28 transplant recipients with a PTLD observed at our institution in an attempt to determine the response to therapy in 25 treated patients with reduction of immunosuppressants, monoclonal antibodies, surgery and/or chemotherapy after a median of follow-up of 60 months (range 4–84 months).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Penn I. Cancers after cyclosporine therapy. Transplant Proc 20 1988; suppl 1: 276–279.
Penn I. Cancers complicating organ transplantation. N Engl J Med 1990; 323: 1767–1769.
Opelz G, Henderson R, for the Collaborative Transplant Study: Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514–1516.
Leblond V, Sutton L, Dorent R et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995; 13: 961–968.
Frizzera G, Hanto DW, Gajl-Peczalska KJ et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262–4271.
Locker J, Nalesnik M. Molecular genetic analysis of lymphoid tumors arising after organ transplantation. Am J Pathol 1989; 135: 977–987.
Brousset P, Chittal S, Schlaifer, and al. Detection of Epstein-Barr virus messenger RNA in Reed-Steinberg cells of Hodgkin’s disease by in situ hybridization with biotynylated probes on specially processed modified acetone methyl benzoate xylene (ModAMeX) sections. Blood 1991; 77: 1781–1786.
Stephan JL, Le Deist F, Blanche S et al. Treatment of central nervous system B lymphoproliferative syndrome by local infusion of a B cell-specific monoclonal antibody. Transplantation 1992; 54: 246–248.
Fischer A, Blanche S, Le Bidois J et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324: 1451–1456.
Elias L, Portlock CS, Rosenberg SA. Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer 1978; 42: 1705–1710.
Velasquez WS, Swan F, Redman JR et al. Combination of Etoposide, high-dose Ara-C and Solumedrol with or without Platinol in relapsing or resistant lymphoma. Proc ASCO 1988; 256A (abst).
Nalesnik MA, Jaffe R, Starzl TE et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A — prednisone immunosuppression. Amer J Path 1988; 133: 173–192.
Hanto DW, Frizzera G, Galj-Peczalska et al. Epstein-Barr virus, immunodeficiency, and B-cell lymphoproliferation. Transplantation 1985; 39: 461–472.
Cleary ML, Warnke F, Sklar J. Monoclonality of lymphoproliferative lesions in cardiac- transplant recipients. N Engl J Med 1984; 310: 477–482.
Hanto DW, Galj-Peczalska KJ, Frizzera G et al. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Ann Surg 1983; 198: 356–369.
Cleary ML, Nalesnik MA, Shearer WT et al. Clonal analysis of transplant-associated lymphoproliferations based on the structure of the genomic termini of the Epstein-Barr virus. Blood 1988; 72: 349–352.
Young L, Alfieri C, Henessy K et al. Expression of Epstein-Barr virus transformation associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989; 321: 1080–1085.
Ho M, Jaffe R, Miller G et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988; 45: 719–121.
Waller EK, Ziemianska M, Bangs CD et al. Characterization of posttransplant lymphomas that express T-cell-associated markers: immunophenotypes, molecular genetics, cytogenetics, and heterotransplantation in severe combined immunodeficient mice. Blood 1993; 82: 247–261.
Starzl TE, Nalesnik MA, Porter KA et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1984; i: 583–588
Murray RJ, Kurilla MG, Griffin HM et al. Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses Proc Natl Acad Sci USA 1990; 87: 2906–2910.
Pirsch JD, Stratta RJ, Sollinger HW et al. Treatment of severe Epstein-Barr virus induced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation. Am J Med 1989; 86: 241–244.
Shapiro RS, Chauvenet A, McGuire W et al. Treatment of B-cell lymphoproliferative disorders with interferonα and intravenous gammaglobulin. N Engl J Med 1988; 318: 1334 (letter).
Baiocchi RA, Caligiuri A. Low dose IL2 prevents the development of Epstein-Barr virus-associated lymphoproliferative disorder in the SCID-human mouse Blood 1993; 82: suppl 1, 385A (abst.).
Buchsbaum RJ, Lieberman J. EBV-specific CTL protect against human lymphoma in SCID mice. Blood 1994; 84, suppl 1: 2074 (abst).
Heslop HE, Smith CYK, Loftu S et al. Use of genetically marked virus specific T cytotoxic T lymphocytes to control Epstein-Barr virus related lymphoproliferative Blood 1994–84, suppl 1: 426 (abst).
Papadopoulos EB, Ladanyi M, Emmanuel D et al. Infusions of donor leucocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185–91.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers
About this chapter
Cite this chapter
Leblond, V. et al. (1996). Therapeutic issues in lymphoproliferative disorders: Treatment and outcome of 28 cases observed in a single center. In: Touraine, J.L., Traeger, J., Bétuel, H., Dubernard, J.M., Revillard, J.P., Dupuy, C. (eds) Cancer in Transplantation: Prevention and Treatment. Transplantation and Clinical Immunology, vol 27. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0175-9_30
Download citation
DOI: https://doi.org/10.1007/978-94-009-0175-9_30
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6563-4
Online ISBN: 978-94-009-0175-9
eBook Packages: Springer Book Archive